
News|Articles|January 29, 2024
Alternative buffer management strategies to achieve downstream process improvements
Author(s)Avantor
Buffers are used in great quantities when producing monoclonal antibodies (mAbs), and many biopharmaceutical companies — even large ones — do not have the processing capacity or infrastructure in-house to handle these large volumes. Whether it’s providing quality, pre-weighed, GMP-compliant raw materials or the entire buffer preparation step, there are options available to optimize your process.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
2
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
3
How Codexis is Redefining Pharma Biocatalysis
4
Johnson & Johnson’s Tecvayli Combo Wins FDA National Priority Voucher
5